Vivus, a biotech firm, shares are up 25c to $9.25 and the notable trade was the purchase of 14,902 (now total of 15,200) of the September $20 calls at the 45c ask. But this does not appear to be bullish bet, rather a closing transaction of a position opened on 5/11 when the shares were around $12.50 and option was 90c. The FDA is expected to deliver a decision regarding its weight loss drug on July, 15. Implied volatility has been climbing, up 3% today to the 140% level.